Perrigo reports Q1 2026 earnings with impairment charges, debt loss, and infant formula under review

Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read

Key Changes

• high

  Q1 2026 results included impairment charges and a loss on debt extinguishment, signaling potential asset write-downs and financing challenges during the quarter.

  Item 2.02 verify on EDGAR →
• high

  Infant formula business is under strategic review and excluded from 'Core' metrics; company recorded remediation costs in Q1 with unpredictable future charges expected.

  8-K: Non-GAAP adjustments verify on EDGAR →
• high

  Multiple non-GAAP adjustments in Q1 including restructuring charges, unusual litigation expenses, and losses on divestitures suggest ongoing operational restructuring.

  8-K: Non-GAAP items verify on EDGAR →